Four tips for marketing in the pharma supply chain in a post-pandemic world

10 August 2021

Raman Sehgal, the founder of ramarketing, provides an Expert View on how pharmaceutical and life sciences businesses can market themselves in the post-pandemic environment.

I’ve spent the past two decades working in marketing roles within the global pharma and biotech industry. Sexy, I know. It’s fair to say I’ve seen the good, the bad and the drab.

What did the pandemic do to the world of life sciences? Accelerate everything. From vaccine development, manufacturing and approval timelines to investment in the sector and the way companies find, engage and convert new customers, the pandemic changed the way companies interact forever.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK